Questioning Future Combinations and Targets for CAR T Cell in DLBCL

Lori A. Leslie, MD, discusses chimeric antigen receptor T-cell therapy as a treatment for diffuse large B-cell lymphoma and the positive results demonstrated for this agent in patients with relapsed/refractory disease.

Lori A. Leslie, MD, a lymphoma oncologist at the John Theurer Cancer Center at Hackensack University Medical Center, discusses chimeric antigen receptor (CAR) T-cell therapy as a treatment for diffuse large B-cell lymphoma (DLBCL) and the positive results demonstrated for this agent in patients with relapsed/refractory disease.

This is an exciting space, Leslie says. CAR T-cell therapies have shown long-term remissions of about 40%. Leslie is particularly interested in the mechanisms of resistance because even though CAR T-cell therapies are effective, she wants to know why certain patients are progressing or having a lack of response. This may be because of the loss of CD19 or different CD19 epitopes, Leslie suggests.

Further development of CAR T-cell therapy will bring up other questions, such as what other therapies can be combined with it and how we can create different targets for CAR T-cell therapy in order to increase efficacy and produce more long-term complete responses, according to Leslie.

<< View more resources and information regarding DLBCL